Delray Beach, FL – The American IV Association (AIVA) is proud to announce the launch of its first-ever industry-wide study, aiming to elevate safety standards and improve patient outcomes in the growing field of intravenous (IV) therapy. Named the “Multi-Site Observational Study on the Incidence and Nature of Adverse Events Associated with Intravenous Therapy,” this research will provide critical insights into the safety and risks of IV therapy treatments across the country.
About the Study
The study, conducted across multiple AIVA-affiliated clinics, seeks to determine the incidence rate, types, and severity of adverse events (AEs) experienced during IV therapy. This groundbreaking research involves collecting detailed clinical data using a standardized framework to track potential risks and improve safety protocols.
“We want this study to set the foundation for standardized safety guidelines in IV therapy,” said Dr. Steve Rallis, Scientific Advisory Board Member at the American IV Association. “By gathering robust data and understanding the factors contributing to adverse events, we aim to make IV therapy safer and more effective for patients.”
Study Snapshot
Duration: 30 days
Participants: Patients receiving IV therapy at participating clinics
Primary Goal: To measure the incidence of adverse events and categorize their severity
Adverse Event Severity
The study will classify AEs using a grading scale adapted from the Common Terminology Criteria for Adverse Events (CTCAE):
– Grade 1 (Mild): Transient symptoms not requiring intervention (e.g., slight headache).
– Grade 2 (Moderate): Symptoms requiring medical intervention (e.g., nausea resolved with medication).
– Grade 3 (Severe): Requires clinical management or termination of therapy.
– Grade 4 (Life-threatening): Emergency intervention required.
– Grade 5 (Death): Fatal outcomes related to IV therapy.
Key Objectives
1. Establish the incidence rate of AEs during IV therapy.
2. Categorize AEs by type and severity.
3. Identify risk factors, such as patient characteristics and infusion types.
4. Provide foundational data for the development of future safety guidelines and practitioner training.
What the Data Will Tell Us
Clinics will track patient demographics, infusion details, adverse event reporting, and outcomes in real time through a standardized digital system. This information will be used to identify correlations between infusion types and AEs, as well as opportunities for enhanced safety practices.
Why This Study Matters
With IV therapy evolving as a popular wellness and medical treatment, the need for evidence-based safety protocols has never been greater. The findings will be published in the American IV Association Journal and will guide safety protocols, practitioner training, and the establishment of a national safety registry.
Next Steps and Commitment to Transparency
The AIVA is committed to sharing its findings with the public and the medical community to drive positive change in IV therapy safety. “Safety and transparency are at the core of this initiative,” said Chief Operating Officer David Light, “This study is just the beginning of our efforts to shape a safer and more informed future for IV therapy.”
About the American IV Association
The American IV Association (AIVA) is the leading advocate for safety, education, and exceptional quality standards in intravenous therapy. By developing research-backed protocols and fostering professional development, AIVA empowers clinics and practitioners while enhancing patient care and ensuring business and industry sustainability.